Resources Repository
-
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Government/Law | Economics/Finance | North America | Infectious Diseases | Mathematical Models | State-Transition | Benefit-Cost Analysis | Policy/Regulation | Business/Industry | Health/Medicine -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Government/Law | Economics/Finance | Middle East & North Africa | Infectious Diseases | Decision Theory | Costing Methods | Health Outcomes | State-Transition | Decision Analysis | Policy/Regulation | Health/Medicine -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Government/Law | Economics/Finance | North America | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Health/Medicine | Science/Technology | Europe -
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Government/Law | Economics/Finance | North America | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Test Performance | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Government/Law | Economics/Finance | North America | Infectious Diseases | Costing Methods | Health Outcomes | Test Performance | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology -
Tutorial/PrimerPublication, Teaching Resource 2015White Paper: Retrospective Benefit-Cost Analysis
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote …
In this article the authors consider how benefit-cost analysis can be used retrospectively to promote understanding of the impacts after a policy is implemented. Serving as a brief primer, the authors propose that analysis can be useful for identifying needed reforms as well as in improving the conduct of future prospective analyses. The major challenges relate to estimating what would have occurred in the absence of the policy and separating the effects of the policy…
Government/Law | Economics/Finance | North America | Environmental Health | Priority Setting/Ethics | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Culture/Society | College | Graduate | Doctoral | Critical Thinking/Analysis | Policy Translation -
Working PaperPublication 2015Benefit-Cost Analysis and the Cities
This paper provides a short introduction to the use of benefit-cost analysis to assess interventions …
This paper provides a short introduction to the use of benefit-cost analysis to assess interventions undertaken at the city or municipal level. It introduces the concepts that underlie the conduct of benefit-cost analysis, describes the major analytic components, and discusses how to tailor the analysis to the characteristics of the policy and the resources available. It concludes with a list of references for those interested in learning more.
Government/Law | Economics/Finance | North America | Environmental Health | Preferences/Values | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Climate/Environment | Culture/Society | Critical Thinking/Analysis -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Government/Law | Economics/Finance | North America | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Government/Law | Economics/Finance | North America | Environmental Health | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Technology Assessment | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Energy/Engineering | Health/Medicine